Table 3.

Ocular oncologists and oculoplastic surgeons screening recommendations for MTS

	Ocular oncologists, n (%)	Oculoplastic surgeons, n (%)
What prompts evaluation for MTS?
Do not evaluate	5/31 (16)	5/16 (32)
All sebaceous neoplasms	6/31 (19)	7/16 (44)
Amsterdam II criteria	3/31 (10)	0/16 (0)
Revised Bethesda guidelines	1/31 (3)	1/16 (6)
Visceral neoplasm	17/31 (55)	3/16 (19)
Well-differentiated sebaceous neoplasms	6/31 (19)	2/16 (13)
Sebaceous neoplasm with abnormal IHC/MSI	5/31 (16)	3/16 (19)
Pathologist recommendation	13/31 (42)	4/16 (25)
Young age	4/31 (13)	1/16 (6)
How do you evaluate for MTS?
Non-ocular oncologists	18/31 (58)	8/14 (57)
Geneticist	9/31 (29)	1/14 (7)
Gastroenterologist	8/31 (26)	4/14 (29)
PET/CT	8/31 (26)	0/14 (0)
Pathologist	11/31 (35)	4/14 (29)
Other	2/31 (6)	3/14 (21)
How do you use IHC?
Pathologist's discretion	15/31 (48)	8/16 (50)
All sebaceous neoplasms	5/31 (16)	4/16 (25)
Well-differentiated sebaceous neoplasms	7/31 (23)	1/16 (6)
Personal/family history concerning for MTS	9/31 (29)	3/16 (19)
Other	4/31 (13)	1/16 (6)
How do you use MSI?
Pathologist's discretion	18/31 (58)	11/16 (69)
All sebaceous neoplasms	2/31 (6)	2/16 (13)
Well-differentiated sebaceous neoplasms	5/31 (16)	0/16 (0)
Abnormal IHC	4/31 (13)	0/16 (0)
Personal/family history concerning for MTS	6/31 (19)	0/16 (0)
Geneticist's recommendation	4/31 (13)	1/16 (6)
Other	4/31 (13)	2/16 (13)
How do you use gene mutation studies?
Pathologist's discretion	19/31 (61)	12/16 (75)
All sebaceous neoplasms	1/31 (3)	1/16 (6)
Well-differentiated sebaceous neoplasms	3/31 (10)	0/16 (0)
Abnormal IHC/MSI	6/31 (19)	0/16 (0)
Personal/family history concerning for MTS	5/31 (16)	0/16 (0)
Geneticist's recommendation	6/31 (19)	1/16 (6)
Other	4/31 (13)	2/16 (13)

MTS, Muir-Torre syndrome; IHC, immunohistochemistry; MSI, microsatellite instability.